The Latest Breaking News from Biogen

We often hear about dementia breakthroughs in the news – new genes being discovered, new blood tests being developed, new drugs being tested.

We often hear about “dementia breakthroughs” in the news – new genes being discovered, new blood tests being developed, new drugs being tested.

Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement, though, until they could scrutinize the full peer-reviewed data.

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.

"These peer-reviewed, published results show lecanemab will provide patients more time to participate in daily life and live independently," the Alzheimer's Association said.

Data supports claims that a new drug reduced cognitive and functional decline in Alzheimer's patients by 27 per cent in a clinical trial.

Stock futures nudge higher will Powell, jobs data in focus; Powell speech may challenge Fed's new rate hike outlook; Sam Bankman-Fried set for DealBook summit appearance after FTC collapse; Biogen shares jump after promising Alzheimer's treatment data and HPE shares surge after Q4 earnings beat, solid near-term outlook.

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

Eisai Co. unveiled much-anticipated findings on its experimental Alzheimer’s drug, providing tinder for the hot debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.

Biogen stock surged Wednesday after partner Eisai unveiled Alzheimer's treatment test results that two doctors reportedly described as "magnificent."